Terms: = Brain cancer AND MAX, MGC36767, 4149, ENSG00000125952, MGC18164, MGC10775, P61244, MGC11225, orf1, MGC34679 AND Prognosis
44 results:
1. PDZK1 is correlated with DCE-MRI perfusion parameters in high-grade glioma.
Zhang Y; Wang F; Huang Y
Clinics (Sao Paulo); 2024; 79():100367. PubMed ID: 38692010
[TBL] [Abstract] [Full Text] [Related]
2. Protoporphyrin IX in serum of high-grade glioma patients: A novel target for disease monitoring via liquid biopsy.
Walke A; Krone C; Stummer W; König S; Suero Molina E
Sci Rep; 2024 Feb; 14(1):4297. PubMed ID: 38383693
[TBL] [Abstract] [Full Text] [Related]
3. Individualized discrimination of tumor progression from treatment-related changes in different types of adult-type diffuse gliomas using [
Chen Q; Wang K; Ren X; Zhao X; Chen Q; Fan D; Zhang S; Li X; Ai L
J Neurooncol; 2023 Dec; 165(3):547-559. PubMed ID: 38095773
[TBL] [Abstract] [Full Text] [Related]
4. 68 Ga-PSMA-11 PET/CT Imaging in brain Gliomas and Its Correlation With Clinicopathological Prognostic Parameters.
Verma P; Singh BK; Sudhan MD; Singh RK; Bagul SD; Chandak AR; Soni BK; Shelly D; Basu S
Clin Nucl Med; 2023 Dec; 48(12):e559-e563. PubMed ID: 37883060
[TBL] [Abstract] [Full Text] [Related]
5. AI-based Virtual Synthesis of Methionine PET from Contrast-enhanced MRI: Development and External Validation Study.
Takita H; Matsumoto T; Tatekawa H; Katayama Y; Nakajo K; Uda T; Mitsuyama Y; Walston SL; Miki Y; Ueda D
Radiology; 2023 Aug; 308(2):e223016. PubMed ID: 37526545
[TBL] [Abstract] [Full Text] [Related]
6. Development and validation of a radiomics-based prediction pipeline for the response to stereotactic radiosurgery therapy in brain metastases.
Du P; Liu X; Xiang R; Lv K; Chen H; Liu W; Cao A; Chen L; Wang X; Yu T; Ding J; Li W; Li J; Li Y; Yu Z; Zhu L; Liu J; Geng D
Eur Radiol; 2023 Dec; 33(12):8925-8935. PubMed ID: 37505244
[TBL] [Abstract] [Full Text] [Related]
7. Prediction of Ki-67 labeling index, ATRX mutation, and MGMT promoter methylation status in IDH-mutant astrocytoma by morphological MRI, SWI, DWI, and DSC-PWI.
Yang X; Hu C; Xing Z; Lin Y; Su Y; Wang X; Cao D
Eur Radiol; 2023 Oct; 33(10):7003-7014. PubMed ID: 37133522
[TBL] [Abstract] [Full Text] [Related]
8. brain exposure of osimertinib in patients with epidermal growth factor receptor mutation non-small cell lung cancer and brain metastases: A positron emission tomography and magnetic resonance imaging study.
Ekman S; Cselényi Z; Varrone A; Jucaite A; Martin H; Schou M; Johnström P; Laus G; Lewensohn R; Brown AP; van der Aart J; Vishwanathan K; Farde L
Clin Transl Sci; 2023 Jun; 16(6):955-965. PubMed ID: 36808835
[TBL] [Abstract] [Full Text] [Related]
9. An integrative non-invasive malignant brain tumors classification and Ki-67 labeling index prediction pipeline with radiomics approach.
Zhang L; Liu X; Xu X; Liu W; Jia Y; Chen W; Fu X; Li Q; Sun X; Zhang Y; Shu S; Zhang X; Xiang R; Chen H; Sun P; Geng D; Yu Z; Liu J; Wang J
Eur J Radiol; 2023 Jan; 158():110639. PubMed ID: 36463703
[TBL] [Abstract] [Full Text] [Related]
10. TSPO PET signal using [
Quach S; Holzgreve A; Kaiser L; Unterrainer M; Dekorsy FJ; Nelwan DV; Bartos LM; Kirchleitner SV; Weller J; Weidner L; Niyazi M; Ruf VC; Herms J; Stöcklein S; Wetzel C; Riemenschneider MJ; V Baumgarten L; Thon N; Brendel M; Rupprecht R; Bartenstein P; Tonn JC; Albert NL
Eur J Nucl Med Mol Imaging; 2023 Feb; 50(3):859-869. PubMed ID: 36329288
[TBL] [Abstract] [Full Text] [Related]
11. Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging.
Yang X; Xing Z; She D; Lin Y; Zhang H; Su Y; Cao D
BMC Med Imaging; 2022 May; 22(1):105. PubMed ID: 35644621
[TBL] [Abstract] [Full Text] [Related]
12. Established Serum Biomarkers Are Prognostic Factors in Patients With Oligometastatic cancer and brain Involvement.
Nieder C; Dalhaug A; Mannsåker B
In Vivo; 2022; 36(2):801-805. PubMed ID: 35241535
[TBL] [Abstract] [Full Text] [Related]
13. Dynamic susceptibility contrast-MRI parameters, ADC values, and the T2-FLAIR mismatch sign are useful to differentiate between H3-mutant and H3-wild-type high-grade midline glioma.
Kurokawa R; Kurokawa M; Baba A; Ota Y; Kim J; Capizzano A; Srinivasan A; Moritani T
Eur Radiol; 2022 Jun; 32(6):3672-3682. PubMed ID: 35022811
[TBL] [Abstract] [Full Text] [Related]
14. The Role of FDG-PET and Whole-Body MRI in High Grade Bone Sarcomas With Particular Focus on Osteosarcoma.
Farina A; Gasperini C; Aparisi Gómez MP; Bazzocchi A; Fanti S; Nanni C
Semin Nucl Med; 2022 Sep; 52(5):635-646. PubMed ID: 34879906
[TBL] [Abstract] [Full Text] [Related]
15. Differentiation between supratentorial pilocytic astrocytoma and extraventricular ependymoma using multiparametric MRI.
Zhou X; Su Y; Huang W; Lin X; Xing Z; Cao D
Acta Radiol; 2022 Dec; 63(12):1661-1668. PubMed ID: 34709088
[TBL] [Abstract] [Full Text] [Related]
16. Effectiveness of bortezomib and temozolomide for eradication of recurrent human glioblastoma cells, resistant to radiation.
Pak O; Zaitsev S; Shevchenko V; Sharma A; Sharma HS; Bryukhovetskiy I
Prog Brain Res; 2021; 266():195-209. PubMed ID: 34689859
[TBL] [Abstract] [Full Text] [Related]
17. Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial.
Duerinck J; Schwarze JK; Awada G; Tijtgat J; Vaeyens F; Bertels C; Geens W; Klein S; Seynaeve L; Cras L; D'Haene N; Michotte A; Caljon B; Salmon I; Bruneau M; Kockx M; Van Dooren S; Vanbinst AM; Everaert H; Forsyth R; Neyns B
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34168003
[TBL] [Abstract] [Full Text] [Related]
18. Prediction of H3K27M-mutant brainstem glioma by amide proton transfer-weighted imaging and its derived radiomics.
Zhuo Z; Qu L; Zhang P; Duan Y; Cheng D; Xu X; Sun T; Ding J; Xie C; Liu X; Haller S; Barkhof F; Zhang L; Liu Y
Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4426-4436. PubMed ID: 34131804
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic value of [
Krebs S; Mauguen A; Yildirim O; Hatzoglou V; Francis JH; Schaff LR; Mellinghoff IK; Schöder H; Grommes C
Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):3940-3950. PubMed ID: 33966087
[TBL] [Abstract] [Full Text] [Related]
20. Mapping tumour heterogeneity with pulsed 3D CEST MRI in non-enhancing glioma at 3 T.
Warnert EAH; Wood TC; Incekara F; Barker GJ; Vincent AJP; Schouten J; Kros JM; van den Bent M; Smits M; Tamames JAH
MAGMA; 2022 Feb; 35(1):53-62. PubMed ID: 33606114
[TBL] [Abstract] [Full Text] [Related]
[Next]
